To include its diabetes medications in CVS’s template formulary, the Zydus Lifesciences has announced a strategic partnership with CVS Caremark, starting 1 January 2025.
Drugs Formulary
The added products included, Zituvio (sitagliptin), Zituvimet (sitagliptin and metformin hydrochloride), and Zituvimet XR (extended-release sitagliptin and metformin hydrochloride).
Diabetes Drugs
The medications are aimed at improving glycemic control in adults with Type 2 Diabetes and it was already approved by the USFDA through the 505(b)(2) route.
Message From President & CEO
President and CEO of Zydus Pharmaceuticals USA Inc., Punit Patel emphasized the significance of the partnership. He said that the initiative surely aligned with Zydus‘ commitment to increasing access to high-quality and cost-effective diabetes treatments.
“The collaboration is seen as a validation of Zydus’ strategic investments in its 505(b)(2) product portfolio”, Patel added.
Patel further said that it will help further expand its presence in the US market for diabetes drugs. According to IQVIA, the diabetes drugs sector has seen substantial growth, with the U.S. market for DPP-IV inhibitors and their combinations valued at approximately $10 billion (as of August 2023).
Moreover, the agreement indeed highlighted the Zydus’ efforts to provide differentiated and affordable medications, benefiting both patients and the healthcare system.
About Zydus
Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company. The company discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27,000 people worldwide, including 1,400 scientists engaged in R & D. It is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.